Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073307 · ClinicalTrials.gov registry record · Phase 3
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 903
- Enrollment target
NCT00073307 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 903 participants.
The verdict
NCT00073307, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 903 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2003-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073307
The ClinicalTrials.gov registry entry for NCT00073307 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 903 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00073307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073307 about?
NCT00073307 is a clinical study titled "Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer". The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.
What is the current status of trial NCT00073307?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 903 participants. The study started on 2003-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00073307?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00073307?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.